Deferred registration - Quotient Sciences code: QSC303694

ISRCTN	ISRCTN14668776
DOI	https://doi.org/10.1186/ISRCTN14668776
Integrated Research Application System (IRAS)	1013199
CRO Study Code	QSC303694
Sponsor	Neurocol Operations Sàrl
Funder	Neurocol Operations Sàrl

Submission date: 04/06/2026
Registration date: 24/06/2026
Last edited: 24/06/2026

Recruitment status: Not yet recruiting
Overall study status: Deferred
Condition category: Other

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Contact information

Dr David Everton
Principal investigator

Mere Way, Ruddington Fields
Ruddington
Nottingham
NG11 6JS
United Kingdom

Phone	+44 (0)1159749000
Email	recruitment@weneedyou.co.uk

Clinical Operations
Scientific, Public

Avenue de la Gare 39
Lausanne
1003
Switzerland

Phone	+41 (0)21 711 3970
Email	info@oculis.com

Study information

Primary study design	Interventional
Allocation	N/A: single arm study
Masking	Open (masking not used)
Control	Uncontrolled
Assignment	Single
Purpose	Phase I study in healthy volunteers
Scientific title	CTIMP - Quotient Sciences code: QSC303694 [The full scientific title will be added on or before the deferral expiry date]
Study objectives	This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Ethics approval(s)	Approved 08/06/2026, London – Harrow Research Ethics Committee (Health Research Authority, 2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)2071048357; harrow.rec@hra.nhs.uk), ref: 26/LO/0330
Health condition(s) or problem(s) studied	Healthy volunteers
Intervention	This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Intervention type	Drug
Phase	Phase I
Drug / device / biological / vaccine name(s)	This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Primary outcome measure(s)	[Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Key secondary outcome measure(s)
Completion date	12/08/2026

Eligibility

Participant type(s)
Age group	Mixed
Lower age limit	18 Years
Upper age limit	65 Years
Sex	Male
Target sample size at registration	8
Key inclusion criteria	This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Key exclusion criteria	This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Date of first enrolment	06/07/2026
Date of final enrolment	12/08/2026

Locations

Countries of recruitment

United Kingdom
England

Study participating centre

Quotient Sciences Limited

Mere Way, Ruddington Fields
Ruddington
Nottingham
NG11 6JS
England

Results and Publications

Individual participant data (IPD) Intention to share	No

Editorial Notes

04/06/2026: Study's existence confirmed by the MHRA.